Horizon Discovery Group PLC (LON:HZD) had its price objective reduced by analysts at Panmure Gordon from GBX 270 ($3.52) to GBX 205 ($2.68) in a note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the stock. Panmure Gordon’s target price points to a potential upside of 30.57% from the stock’s current price.

A number of other brokerages have also issued reports on HZD. Numis Securities Ltd restated a “buy” rating and issued a GBX 252 ($3.29) price target on shares of Horizon Discovery Group PLC in a research note on Wednesday, June 1st. Beaufort Securities restated a “speculative buy” rating on shares of Horizon Discovery Group PLC in a research note on Friday, September 2nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of GBX 217.25 ($2.84).

Shares of Horizon Discovery Group PLC (LON:HZD) opened at 156.40 on Tuesday. Horizon Discovery Group PLC has a 1-year low of GBX 125.00 and a 1-year high of GBX 188.06. The firm’s market cap is GBX 147.16 million. The stock has a 50 day moving average of GBX 160.22 and a 200 day moving average of GBX 160.62.

Horizon Discovery Group PLC Company Profile

Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.

Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.